IN2015DN00335A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00335A
IN2015DN00335A IN335DEN2015A IN2015DN00335A IN 2015DN00335 A IN2015DN00335 A IN 2015DN00335A IN 335DEN2015 A IN335DEN2015 A IN 335DEN2015A IN 2015DN00335 A IN2015DN00335 A IN 2015DN00335A
Authority
IN
India
Prior art keywords
disorders
diseases
compounds
formula
methods
Prior art date
Application number
Other languages
English (en)
Inventor
James Breitenbucher
Brya BRANSTETTER
Brian Dyck
Laurent Gomez
Andrew Richard Hudson
Tami Jo Marrone
Troy Vickers
Marco Peters
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of IN2015DN00335A publication Critical patent/IN2015DN00335A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IN335DEN2015 2012-06-18 2013-06-18 IN2015DN00335A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661091P 2012-06-18 2012-06-18
PCT/US2013/046403 WO2013192225A1 (en) 2012-06-18 2013-06-18 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds

Publications (1)

Publication Number Publication Date
IN2015DN00335A true IN2015DN00335A (zh) 2015-06-12

Family

ID=49756458

Family Applications (2)

Application Number Title Priority Date Filing Date
IN335DEN2015 IN2015DN00335A (zh) 2012-06-18 2013-06-18
IN334DEN2015 IN2015DN00334A (zh) 2012-06-18 2013-06-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN334DEN2015 IN2015DN00334A (zh) 2012-06-18 2013-06-18

Country Status (18)

Country Link
US (7) US9499562B2 (zh)
EP (3) EP3489238B8 (zh)
JP (2) JP6129960B2 (zh)
KR (2) KR102087756B1 (zh)
CN (2) CN104583213B (zh)
AU (3) AU2013277294C1 (zh)
BR (2) BR112014031730B1 (zh)
CA (2) CA2877149C (zh)
DK (2) DK3489238T3 (zh)
ES (2) ES2904267T3 (zh)
HK (2) HK1208024A1 (zh)
IL (2) IL236233A (zh)
IN (2) IN2015DN00335A (zh)
MX (2) MX357320B (zh)
NZ (2) NZ703949A (zh)
RU (2) RU2653054C2 (zh)
SG (3) SG11201408395WA (zh)
WO (2) WO2013192225A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526020T1 (de) * 2000-08-10 2011-10-15 Cold Spring Harbor Lab Gesteigertes kognitives training
SG11201408395WA (en) 2012-06-18 2015-01-29 Dart Neuroscience Cayman Ltd Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds
JP6396229B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396231B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396230B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
GB201406486D0 (en) * 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017046603A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds and new uses thereof
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JOP20170164A1 (ar) 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
BR112018013247A2 (pt) 2016-10-28 2018-12-04 H Lundbeck As tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
US10912773B2 (en) 2016-10-28 2021-02-09 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物
US11066419B2 (en) * 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
EP3585392A1 (en) * 2017-02-23 2020-01-01 Boehringer Ingelheim International GmbH New medical use of compound iii
AR112457A1 (es) 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
AR112346A1 (es) * 2017-08-10 2019-10-16 Lilly Co Eli Derivados de [1,2,4]triazolo
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
WO2021035157A1 (en) * 2019-08-22 2021-02-25 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046366A1 (de) * 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3146599A1 (de) 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0181282A1 (de) 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
JPS62135475A (ja) * 1985-09-30 1987-06-18 チバ−ガイギ−　アクチエンゲゼルシヤフト ２−置換−ｅ−融合−〔１，２，４〕トリアゾロ−〔１，５−Ｃ〕ピリミジン
EP0217748B1 (en) * 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2659329B1 (fr) * 1990-03-09 1994-06-03 Adir Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US6110973A (en) * 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
ES2166270B1 (es) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE10012373A1 (de) * 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
ATE526020T1 (de) 2000-08-10 2011-10-15 Cold Spring Harbor Lab Gesteigertes kognitives training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
FR2897061B1 (fr) 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
MX2008015489A (es) * 2006-06-06 2009-01-13 Intra Cellular Therapies Inc Compuestos organicos.
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
KR20100017422A (ko) 2007-05-15 2010-02-16 헬리콘 테라퓨틱스 인코퍼레이티드 작은 간섭 ＲＮＡ(ｓｉＲＮＡ)를 이용하여 기억 형성에 관여하는 유전자를 확인하는 방법
JP5265687B2 (ja) * 2007-09-26 2013-08-14 ジーイー・ヘルスケア・バイオサイエンス・バイオプロセス・コーポレイション 三次元の使い捨てバイオリアクター
CN104370920A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8536159B2 (en) 2008-12-06 2013-09-17 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322905A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC COMPOUNDS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
SG11201408395WA (en) 2012-06-18 2015-01-29 Dart Neuroscience Cayman Ltd Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds

Also Published As

Publication number Publication date
BR112014031730B1 (pt) 2023-05-16
US9175010B2 (en) 2015-11-03
WO2013192229A1 (en) 2013-12-27
NZ703949A (en) 2016-10-28
AU2013277298A1 (en) 2015-02-05
US20190046535A1 (en) 2019-02-14
EP2861605A1 (en) 2015-04-22
CN104583213B (zh) 2018-10-26
AU2017272245B2 (en) 2019-08-29
HK1208023A1 (zh) 2016-02-19
ES2715325T3 (es) 2019-06-03
US9284335B2 (en) 2016-03-15
BR112014031731B1 (pt) 2022-12-06
SG11201408397SA (en) 2015-01-29
IL236233A0 (en) 2015-02-01
HK1208024A1 (zh) 2016-02-19
CA2877146A1 (en) 2013-12-27
US10092575B2 (en) 2018-10-09
MX2014015740A (es) 2015-11-06
JP2015526395A (ja) 2015-09-10
DK3489238T3 (da) 2022-01-10
NZ703950A (en) 2016-10-28
CN104583217B (zh) 2017-11-17
JP6129960B2 (ja) 2017-05-17
WO2013192229A8 (en) 2015-09-03
AU2013277294C1 (en) 2018-02-08
CN104583213A (zh) 2015-04-29
EP2861603A4 (en) 2015-11-11
US20160075719A1 (en) 2016-03-17
RU2015100209A (ru) 2016-08-10
US20160031901A1 (en) 2016-02-04
CA2877146C (en) 2020-10-20
SG10201703253XA (en) 2017-06-29
MX2014015737A (es) 2015-09-16
EP2861605A4 (en) 2016-01-13
AU2013277298B2 (en) 2017-09-07
US9499562B2 (en) 2016-11-22
JP2015526394A (ja) 2015-09-10
CA2877149A1 (en) 2013-12-27
EP3489238B8 (en) 2022-02-16
MX357320B (es) 2018-07-04
US20170182052A1 (en) 2017-06-29
RU2653054C2 (ru) 2018-05-07
BR112014031731A2 (pt) 2017-06-27
EP2861605B1 (en) 2017-05-03
EP2861603B1 (en) 2018-12-19
CN104583217A (zh) 2015-04-29
IL236232A (en) 2016-10-31
KR20150063030A (ko) 2015-06-08
US10376514B2 (en) 2019-08-13
KR20150063028A (ko) 2015-06-08
US10105367B2 (en) 2018-10-23
JP6240180B2 (ja) 2017-11-29
KR102087756B1 (ko) 2020-03-12
US20150158885A1 (en) 2015-06-11
US9533996B2 (en) 2017-01-03
EP3489238B1 (en) 2021-10-13
IL236233A (en) 2016-10-31
IL236232A0 (en) 2015-02-01
DK2861603T3 (en) 2019-03-04
AU2013277294B2 (en) 2017-04-13
SG11201408395WA (en) 2015-01-29
EP3489238A1 (en) 2019-05-29
BR112014031730A2 (pt) 2017-06-27
RU2659779C2 (ru) 2018-07-04
EP2861603A1 (en) 2015-04-22
AU2017272245A1 (en) 2018-01-04
KR102191816B1 (ko) 2020-12-17
AU2013277294A1 (en) 2015-02-05
MX359615B (es) 2018-10-03
ES2904267T3 (es) 2022-04-04
RU2015100213A (ru) 2016-08-10
CA2877149C (en) 2021-01-19
US20130338139A1 (en) 2013-12-19
WO2013192225A1 (en) 2013-12-27
US20170209459A1 (en) 2017-07-27
IN2015DN00334A (zh) 2015-06-12

Similar Documents

Publication Publication Date Title
IN2015DN00335A (zh)
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
PH12015500525A1 (en) Formulations of enzalutamide
IN2015DN01156A (zh)
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
TN2015000516A1 (en) Chemical compounds
MX2015010125A (es) Derivados de piridazinona-amidas.
JO3131B1 (ar) مركبات كيميائية
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
UA112795C2 (uk) Біциклічні піразинонові похідні
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
IN2015DN00372A (zh)
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
MX343377B (es) Carboxamidas azaheterocilcicas de amina ciclica.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
NZ702239A (en) Heteroaryl compounds and methods of use thereof
MX2014007364A (es) Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.